11 February 2020, Kawin Technology's therapeutic drug of chronic hepatitis C virus (HCV) , Coblopasvir Hydrochloride Capsule (trade name: 凯力唯), was approved by National Medical Products Administration through priority review and approval process. This product is used in combination with sofosbuvir for the treatment of chronic HCV genotype 1, 2, 3 and 6 infection in treatment-naïve or interferon-treated adults that with or without compensatory cirrhosis.

Coblopasvir Hydrochloride Capsule is an NS5A inhibitor that inhibits the replication and assembly of HCV by inhibiting NS5A proteins. Supported by National Science and Technology Major Project of the Ministry of Science and Technology of China, the launching facilitates to increase the availability of domestic anti-HCV drugs and to meet the clinical demand of medication.

赛波唯® (Sofosbuvir Tablets) Approved for HCV Treatment NO